• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort

Hoffmann-Vold, Anna-Maria; Fretheim, Håvard Halland; Halse, Anne-Kristine; Seip, Marit; Bitter, Helle; Wallenius, Marianne; Garen, Torhild Oddveig; Salberg, Anne; Brunborg, Cathrine; Midtvedt, Øyvind; Lund, May-Brith; Aaløkken, Trond M; Molberg, Øyvind
Journal article, Peer reviewed
Accepted version
Thumbnail
View/Open
Hoffmann-Vold (471.0Kb)
URI
http://hdl.handle.net/11250/2642447
Date
2019
Metadata
Show full item record
Collections
  • Institutt for nevromedisin og bevegelsesvitenskap [1651]
  • Publikasjoner fra CRIStin - NTNU [19849]
  • Publikasjoner fra Cristin - St. Olavs hospital [312]
  • St. Olavs hospital [526]
Original version
American Journal of Respiratory and Critical Care Medicine. 2019, 200 (10), 1258-1266.   10.1164/rccm.201903-0486OC
Abstract
Rationale: Interstitial lung disease (ILD) represents a major challenge in systemic sclerosis (SSc), but there are no precise, population-based data on its overall impact, limiting opportunities for screening and management strategies. Objectives: Evaluate impact of ILD in a unique, nationwide, population-based SSc cohort. Methods: ILD was assessed prospectively in the Norwegian SSc (Nor-SSc) cohort, including all 815 patients with SSc resident in the country from 2000 to 2012. Lung high-resolution computed tomography (HRCT) scans were available for fibrosis quantification at baseline (n = 650, 80%) and follow-up. Pulmonary function tests were assessed at baseline (n = 703, 86%) and follow-up. Vital status and standardized mortality ratios (SMRs) were estimated at study end (2018) in the 630 incident Nor-SSc cases and 15 individually matched control subjects. Cumulative survival rates were computed. Measurements and Main Results: At baseline, 50% of the subjects with SSc (n = 324) had ILD by HRCT and 46% displayed pulmonary function declines consistent with ILD progression. Mortality correlated with extent of lung fibrosis as SMR increased from 2.2 with no fibrosis to 8.0 with greater than 25% fibrosis. SMR was inversely related to baseline FVC% and increased at all FVC levels below 100%. In patients with normal-range baseline FVC (80–100%), the 5- and 10-year survival rates correlated with presence or absence of lung fibrosis, being 83% and 80%, respectively, with no fibrosis and 69% and 56%, respectively, with lung fibrosis (P = 0.03). Conclusions: The mere presence of ILD at baseline appears to affect outcome in SSc, suggesting that all patients with SSc should undergo a baseline pulmonary function test and lung HRCT screening to diagnose ILD early and tailor further management.
Publisher
American Thoracic Society
Journal
American Journal of Respiratory and Critical Care Medicine

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit